Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.61 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.61 |
| ▸ | BCL6 | P41182 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 8/20 | 0.47 |
| ▸ | PRKCA | P17252 | 3/20 | 0.47 |
| ▸ | CCNK | O75909 | 3/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183265 | 0.90 | KCNN3 (0.76) | KCNN3KCNN2BCL6NPC1SRC | |
| SCHEMBL183217 | 0.83 | NPSR1 (0.57) | KCNN3KCNN2NPC1SRCCDK1 | |
| SCHEMBL244036 | 0.82 | SRC (0.55) | NPC1SRCCDK1PRKCA | |
| SCHEMBL183318 | 0.79 | KCNN3 (0.71) | KCNN3KCNN2BCL6SRCCDK1 | |
| SCHEMBL183708 | 0.78 | KCNN2 (0.70) | KCNN3KCNN2BCL6CDK1POLB | |
| SCHEMBL183670 | 0.78 | KCNN3 (0.69) | KCNN3KCNN2BCL6NPC1SRC | |
| SCHEMBL183176 | 0.76 | KCNN3 (1.00) | KCNN3KCNN2BCL6TP53POLB | |
| SCHEMBL30421528 | 0.76 | KCNN3 (1.00) | KCNN3KCNN2BCL6TP53POLB | |
| SCHEMBL3591520 | 0.76 | KCNN3 (0.58) | KCNN3KCNN2BCL6CDK1POLB | |
| SCHEMBL183487 | 0.73 | KCNN3 (0.79) | KCNN3KCNN2BCL6TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | claimed |
| JP-2010522721-A | — | — | 2010-07-08 | — | — | JP | claimed |
| EP-2144911-A2 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch AS (DK) | 2010-01-20 | — | — | EP | claimed |
| WO-2008116912-A2 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | claimed |
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| EP-2144911-A2 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch AS (DK) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008116912-A2 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116912-A2 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | KCNN3 15/4885KCNN2 5/4885BCL6 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.